Last reviewed · How we verify

Adbry — Competitive Intelligence Brief

Adbry (TRALOKINUMAB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-13 Antagonist [EPC]. Area: Immunology.

marketed Interleukin-13 Antagonist [EPC] Interleukin-13 Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Adbry (TRALOKINUMAB) — Leo Pharma As. Adbry blocks the action of IL-13, a protein that contributes to inflammation and skin barrier disruption in atopic dermatitis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Adbry TARGET TRALOKINUMAB Leo Pharma As marketed Interleukin-13 Antagonist [EPC] Interleukin-13 2021-01-01
Experimental: Tralokinumab Experimental: Tralokinumab AstraZeneca phase 3 Monoclonal antibody; IL-13 inhibitor IL-13 (Interleukin-13)
Ebglyss LEBRIKIZUMAB Eli Lilly And Co marketed Interleukin-13 Antagonist [EPC] 2025-01-01
EBGLYSS LEBRIKIZUMAB-LBKZ ELI LILLY AND CO marketed Interleukin-13 Antagonist [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-13 Antagonist [EPC] class)

  1. ELI LILLY AND CO · 1 drug in this class
  2. Eli Lilly And Co · 1 drug in this class
  3. Leo Pharma As · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Adbry — Competitive Intelligence Brief. https://druglandscape.com/ci/tralokinumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: